From obesity to diabetes and cancer: Epidemiological links and role of therapies

British Journal of Cancer

Volumn 114, Issue 7, 2016, Pages 716-722

  García Jiménez, Custodia ^a   Gutiérrez Salmerón, María ^a   Chocarro Calvo, Ana ^a,b   García Martinez, Jose Manuel ^a   Castaño, Angel ^a,c   De La Vieja, Antonio ^d  

^a UNIVERSIDAD REY JUAN CARLOS   (Spain)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

antidiabetic treatment; antineoplastic therapy; cancer; diabetes; insulin; obesity

Indexed keywords

ACARBOSE; ANTINEOPLASTIC AGENT; INSULIN; METFORMIN; MIGLITOL; SOMATOMEDIN C; ANTIDIABETIC AGENT;

CANCER PATIENT; CANCER RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SOCIAL STATUS; COMPLICATION; DIABETES MELLITUS, TYPE 2; NEOPLASMS;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; NEOPLASMS; OBESITY;

EID: 84959129423     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.37     Document Type: Review

References (43)

1. Adams TD, Stroup AM, Gress RE, Adams KF, Calle EE, Smith SC, Halverson RC, Simper SC, Hopkins PN, Hunt SC (2009) Cancer incidence and mortality after gastric bypass surgery. Obesity (Silver Spring) 17(4): 796-802.
2. Argiles JM, Busquets S, Stemmler B, Lopez-Soriano FJ (2014) Cancer cachexia: understanding the molecular basis. Nat Rev Cancer 14(11): 754-762.
3. Baur DM, Klotsche J, Hamnvik OP, Sievers C, Pieper L, Wittchen HU, Stalla GK, Schmid RM, Kales SN, Mantzoros CS (2011) Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. Metabolism 60(10): 1363-1371.
4. Bosetti C, Rosato V, Buniato D, Zambon A, La Vecchia C, Corrao G (2013) Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-Analysis. Oncologist 18(2): 148-156.
5. Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM (2012) Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus. J Clin Endocrinol Metab 97(7): E1170-E1175.
6. Coller HA (2014) Is cancer a metabolic disease?. Am J Pathol 184(1): 4-17.
7. Ekstrand AI, Jonsson M, Lindblom A, Borg A, Nilbert M (2010) Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer. Fam Cancer 9(2): 125-129.
8. Feng JP, Yuan XL, Li M, Fang J, Xie T, Zhou Y, Zhu YM, Luo M, Lin M, Ye DW (2013) Secondary diabetes associated with 5-fluorouracil-based chemotherapy regimens in non-diabetic patients with colorectal cancer: results from a single-centre cohort study. Colorectal Dis 15(1): 27-33.
9. Garcia-Jimenez C, Garcia-Martinez JM, Chocarro-Calvo A, De la Vieja A (2014) A new link between diabetes and cancer: enhanced WNT/betacatenin signaling by high glucose. J Mol Endocrinol 52(1): R51-R66.
10. Geuna E, Roda D, Rafii S, Jimenez B, Capelan M, Rihawi K, Montemurro F, Yap TA, Kaye SB, De Bono JS, Molife LR, Banerji U (2015) Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials. Br J Cancer 113(11): 1541-1547.
11. Goh LY, Goh KL (2013) Obesity: an epidemiological perspective from Asia and its relationship to gastrointestinal and liver cancers. J Gastroenterol Hepatol 28(Suppl 4): 54-58.
12. Groop PH, Forsblom C, Thomas MC (2005) Mechanisms of disease: pathwayselective insulin resistance and microvascular complications of diabetes. Nat Clin Pract Endocrinol Metab 1(2): 100-110.
13. Habib SL, Rojna M (2013) Diabetes and risk of cancer. ISRN Oncol 2013: 583786.
14. Hara N (2012) Prostate carcinogenesis with diabetes and androgen-deprivationtherapy-related diabetes: an update. Exp Diabetes Res 2012: 801610.
15. Harris D, Barts A, Connors J, Dahl M, Elliott T, Kong J, Keane T, Thompson D, Stafford S, Ur E, Sirrs S (2013) Glucocorticoid-induced hyperglycemia is prevalent and unpredictable for patients undergoing cancer therapy: an observational cohort study. Curr Oncol 20(6): e532-e538.
16. Hassan MM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK, Javle M, Moghazy DM, Lozano RD, Abbruzzese JL, Vauthey JN (2010) Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 116(8): 1938-1946.
17. Hu J, La Vecchia C, Augustin LS, Negri E, De Groh M, Morrison H, Mery L. Canadian Cancer Registries Epidemiology Research Group (2013) Glycemic index, glycemic load and cancer risk. Ann Oncol 24(1): 245-251.
18. Ito Y, Miyamoto T, Chong Y, Maki T, Akashi K, Kamimura T (2013) Nilotinib exacerbates diabetes mellitus by decreasing secretion of endogenous insulin. Int J Hematol 97(1): 135-138.
19. Lee SY, Kurita N, Yokoyama Y, Seki M, Hasegawa Y, Okoshi Y, Chiba S (2014) Glucocorticoid-induced diabetes mellitus in patients with lymphoma treated with CHOP chemotherapy. Support Care Cancer 22(5): 1385-1390.
20. Lutz SZ, Staiger H, Fritsche A, Haring HU (2014) Antihyperglycaemic therapies and cancer risk. Diab Vasc Dis Res 11(6): 371-389.
21. Ma YS, Yang IP, Tsai HL, Huang CW, Juo SH, Wang JY (2014) High glucose modulates antiproliferative effect and cytotoxicity of 5-fluorouracil in human colon cancer cells. DNA Cell Biol 33(2): 64-72.
22. Malmberg K (1997) Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 314(7093): 1512-1515.
23. Meacham LR, Sklar CA, Li S, Liu Q, Gimpel N, Yasui Y, Whitton JA, Stovall M, Robison LL, Oeffinger KC (2009) Diabetes mellitus in long-Term survivors of childhood cancer. Increased risk associated with radiation therapy: a report for the childhood cancer survivor study. Arch Intern Med 169(15): 1381-1388.
24. Nan DN, Fernandez-Ayala M, Vega Villegas ME, Garcia-Castano A, Rivera F, Lopez-Brea M, Gonzalez-Macias J (2003) Diabetes mellitus following cisplatin treatment. Acta Oncol (Madr) 42(1): 75-78.
25. Nauck MA, Meier JJ (2013) Author reply: To PMID 23208166. Ann Intern Med 158(6): 501-502.
26. Nguyen NP, Vos P, Vinh-Hung V, Borok TL, Dutta S, Karlsson U, Lee H, Martinez T, Jo BH, Nguyen LM, Nguyen N, Sallah S (2009) Altered glucose metabolism during chemoradiation for head and neck cancer. Anticancer Res 29(11): 4683-4687.
27. Noto H, Goto A, Tsujimoto T, Osame K, Noda M (2013) Latest insights into the risk of cancer in diabetes. J Diabetes Investig 4(3): 225-232.
28. Origin Trial Investigators, Gerstein H, Yusuf S, Riddle MC, Ryden L, Bosch J (2008) Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention) Am Heart J 155(1): 26-32, 32.e1-6.
29. Pilkey J, Streeter L, Beel A, Hiebert T, Li X (2012) Corticosteroid-induced diabetes in palliative care. J Palliat Med 15(6): 681-689.
30. Pollak M, Russell-Jones D (2010) Insulin analogues and cancer risk: cause for concern or cause celebre?. Int J Clin Pract 64(5): 628-636.
31. Rendell M, Akturk HK, Tella SH (2013) Glargine safety, diabetes and cancer. Expert Opin Drug Saf 12(2): 247-263.
32. Ruiter R, Visser LE, Van Herk-Sukel MP, Coebergh JW, Haak HR, Geelhoed-Duijvestijn PH, Straus SM, Herings RM, Stricker BH (2012) Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based followup study. Diabetes Care 35(1): 119-124.
33. Saglam HS, Kose O, Kumsar S, Budak S, Adsan O (2012) Fasting blood glucose and lipid profile alterations following twelve-month androgen deprivation therapy in men with prostate cancer. ScientificWorldJournal 2012: 696329.
34. Shikata K, Ninomiya T, Kiyohara Y (2013) Diabetes mellitus and cancer risk: review of the epidemiological evidence. Cancer Sci 104(1): 9-14.
35. Singh S, Singh PP, Singh AG, Murad MH, McWilliams RR, Chari ST (2013) Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-Analysis. Am J Gastroenterol 108(4): 510-519; quiz 520.
36. Sjostrom L, Gummesson A, Sjostrom CD, Narbro K, Peltonen M, Wedel H, Bengtsson C, Bouchard C, Carlsson B, Dahlgren S, Jacobson P, Karason K, Karlsson J, Larsson B, Lindroos AK, Lonroth H, Naslund I, Olbers T, Stenlof K, Torgerson J, Carlsson LM. Swedish Obese Subjects Study (2009) Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol 10(7): 653-662.
37. Stocks T, Rapp K, Bjorge T, Manjer J, Ulmer H, Selmer R, Lukanova A, Johansen D, Concin H, Tretli S, Hallmans G, Jonsson H, Stattin P (2009) Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Med 6(12): e1000201.
38. Thakkar B, Aronis KN, Vamvini MT, Shields K, Mantzoros CS (2013) Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-Analysis using primary data of published studies. Metabolism 62(7): 922-934.
39. Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JP (2015) Type 2 diabetes and cancer: umbrella review of meta-Analyses of observational studies. BMJ 350: g7607.
40. Verges B, Cariou B (2015) mTOR inhibitors and diabetes. Diabetes Res Clin Pract 110(2): 101-108.
41. Verges B, Walter T, Cariou B (2014) Endocrine side effects of anti-cancer drugs: effects of anti-cancer targeted therapies on lipid and glucose metabolism. Eur J Endocrinol 170(2): R43-R55.
42. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R (2009) Diabetes and cancer. Endocr Relat Cancer 16(4): 1103-1123.
43. Wu L, Zhu J, Prokop LJ, Murad MH (2015) Pharmacologic therapy of diabetes and overall cancer risk and mortality: a meta-Analysis of 265 studies. Sci Rep 5: 10147.